A unique patent window

When a company develops a drug, it is patented in two stages – the original patent and a secondary patent. When the original patent expires, the secondary succeeds,  often protecting microscopic “fingerprints” of various crystalline forms from being copied.

Today no conventional developing methods are able to produce copies of drugs that are out of scope for the secondary patent protection. As a result of that the original company is able to continue to market it unthreatened by the generic market.

A no fingerprint technology

The unique technology enables Xspray to develop drugs in total absence of  microscopic fingerprints. Unlike the patented forms – the crystalline ones – Xspray’s developing methods provide completely amorphous variants, equivalent to the original drug.

The picture, a topological measurement at microscopic level, shows how Xspray’s fingerprint differ from conventional crystalline forms of drugs. While a crystalline structure shows clear peaks and valleys, an amorphous variant provides no markers.

Since Xspray’s amorphous version has no clear peaks and valleys, the secondary patent becomes uneffective, and Xspray can, as sole competitor, go to market with a more attractive price for both doctors and patients.

A patent window with a multi billion potential

Traditional generic companies can start competing after the secondary patent has expired, creating copies using conventional technology. Since there are a lot of companies developing copes, it means high competition and therefore low margins. Xspray, however, can start competing long before the generic companies, which considerably increases the chances of high margin projects.

If you are able to go to market when the original patent expires there’s often a billion dollar market. Getting in early also gives competitive advantages when the secondary patents expire and the market gets exposed to competition by the generic companies.